Zura Bio (NASDAQ:ZURA) Coverage Initiated at Leerink Partners

Equities researchers at Leerink Partners began coverage on shares of Zura Bio (NASDAQ:ZURA) in a research note issued to investors on Monday, Marketbeat.com reports. The firm set an “outperform” rating and a $15.00 price target on the stock. Leerink Partners’ price objective indicates a potential upside of 264.96% from the stock’s current price.

A number of other research analysts have also recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Piper Sandler restated an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research note on Monday, October 21st. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $16.75.

Zura Bio Price Performance

ZURA opened at $4.11 on Monday. The stock has a fifty day moving average of $4.17 and a 200-day moving average of $4.09. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, equities research analysts predict that Zura Bio will post -0.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the sale, the director now directly owns 2,085,418 shares of the company’s stock, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 22.10% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of Zura Bio in the 2nd quarter worth about $43,000. Renaissance Technologies LLC raised its position in Zura Bio by 51.3% in the second quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the period. SG Americas Securities LLC purchased a new position in Zura Bio in the third quarter valued at about $62,000. Forefront Analytics LLC grew its position in shares of Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of Zura Bio during the 3rd quarter worth approximately $156,000. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.